Latest Information Update: 18 Nov 2003
At a glance
- Originator Bioglan Pharma [CEASED]
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rosacea
Most Recent Events
- 09 Nov 2000 Preregistration for Rosacea in European Union (Unknown route)